ArticleVaccine2025
Emerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-vallent pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short communication.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
- Republished as
Authors and funding
7 authors.
Funding
Abstract
In this study, we describe S. pneumoniae serotype distribution before and after PCV13 rollout in Tanzania. We serotyped S. pneumoniae isolates from two cross-sectional studies, before and after vaccine rollout. The isolates were from children under 5 years old, and in the PCV13 era, only those who had received all doses of PCV13 were eligible. Total of 539 participants with serotyped S. pneumoniae were included. In the pre-vaccine era, 61 (55 %) of S. pneumoniae serotypes were vaccine types, compared to 89 (23.3 %) in the PCV13 era. The most common serotypes in the pre-vaccine period were 19F (n = 23, 20.7 %) and 6B (n = 11, 9.9 %). In the vaccine era, serotypes 15B/C (n = 40, 10.5 %), and 3 (n = 29, 7.6 %) were most prevalent. We observed the emergence of 14 non-vaccine serotypes not detected in the pre-vaccine era. Further surveillance is needed to assess shifts in carriage and their implications for the fight against invasive pneumococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.